#1 Clinical Trials Search in Europe

KETOROLAC

Ketorolac tromethamine is a potent non-steroidal anti-inflammatory drug (NSAID) that has been studied extensively in various clinical settings for pain management. Unlike opioids, ketorolac provides effective pain relief without the risks of dependence or respiratory depression. This article explores how ketorolac is being used in clinical trials across different medical specialties, including ophthalmology, obstetrics, orthopedics, and emergency medicine. We’ll examine different formulations (intravenous, intranasal, and topical), dosing strategies, and how this medication compares to other pain management approaches.

Table of Contents

Introduction to Ketorolac

Ketorolac (also known by brand names such as Toradol, Acular LS, Sprix, and Acuvail) is a potent non-steroidal anti-inflammatory drug (NSAID) that is used for the treatment of moderate to severe pain. It works by inhibiting the body’s production of certain natural substances that cause inflammation, thereby decreasing pain, swelling, and fever[1].

What is Ketorolac?

Ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) that belongs to a group of non-opioid analgesics. It works by inhibiting the synthesis of prostaglandins and thromboxanes, which are substances in the body that cause inflammation and pain[2]. By blocking the cyclooxygenase pathway, ketorolac reduces inflammation and provides strong pain relief without the sedative effects and addiction potential associated with opioid medications.

Unlike opioid medications (such as morphine or oxycodone), ketorolac does not lead to dependence or addiction, making it a valuable option for pain management in various clinical settings. This medication offers a safer alternative for acute pain relief without the risks of respiratory depression, sedation, and potential for misuse that are associated with opioids[3].

Different Forms of Ketorolac

Ketorolac is available in several different formulations, each designed for specific uses:

  • Intravenous (IV) injection: Used in hospital settings for immediate pain relief, often after surgery[4]
  • Intramuscular (IM) injection: Administered as a shot into a muscle for quick pain relief[5]
  • Oral tablets: Used for continued pain management after initial injectable doses[6]
  • Intranasal spray (Sprix): Delivered through the nose for rapid absorption[7]
  • Ophthalmic (eye) solution: Used for eye conditions as drops (Acular LS, Acuvail)[8]
  • Topical gel: Being researched for localized pain relief[9]

Medical Uses

Ketorolac is FDA-approved for the short-term management (up to 5 days) of moderately severe acute pain that requires analgesia at the opioid level. It has been studied and used in various clinical settings, including:

Pain Management Applications

Ketorolac is used to manage many types of pain, including:

  • Postoperative pain: Commonly used after surgeries to reduce the need for opioid medications[10]
  • Renal colic: Effective for the severe pain caused by kidney stones[3]
  • Acute musculoskeletal pain: Used for injuries and severe muscle or joint pain[5]
  • Migraine headaches: Can provide relief from severe migraine pain[2]
  • Post-cesarean section pain: Helps manage pain after childbirth by cesarean section, reducing the need for opioids[4]
  • Gynecologic surgery pain: Used after female pelvic reconstructive surgery[1]
  • Acute gouty arthritis: Being studied for pain relief during gout flares[9]
  • Interstitial cystitis pain flares: Used for short-term management of bladder pain[11]
  • Ankle fracture pain: Administered after surgical treatment of ankle fractures[12]
  • Arthritic knee pain: Some studies explore intra-articular (into the joint) administration[13]
  • Acute pancreatitis: Being investigated for potential benefits in managing inflammation[6]

Eye Conditions and Treatments

In ophthalmology, ketorolac eye drops (Acular LS, Acuvail) are used for:

  • Post-cataract surgery inflammation: Reduces inflammation after cataract removal[14]
  • Post-laser eye surgery pain: Alleviates discomfort after procedures like PRK (photorefractive keratectomy)[15]
  • Seasonal allergic conjunctivitis: Helps manage eye inflammation due to allergies
  • Reducing inflammation during vitreoretinal surgery: Helps maintain pupil size during certain eye surgeries[16]
  • Prevention of cystoid macular edema: Used to prevent fluid buildup in the retina after eye surgery[17]
  • Diabetic retinopathy management: Being researched for potential benefits in reducing inflammation associated with diabetic eye disease[18]

Dosing Information

Ketorolac dosing varies based on the formulation, patient age, weight, and clinical situation. Some general guidelines include:

  • Injectable (IV/IM) for adults: Typically 30mg as a single dose, or 15mg for elderly patients or those weighing less than 50kg[19]
  • Intranasal (Sprix) for adults: 31.5mg (one 15.75mg spray in each nostril) every 6-8 hours[11]
  • Ophthalmic solution: Usually one drop 4 times daily[8]
  • Pediatric dosing: Weight-based dosing is used, typically 0.5mg/kg up to maximum doses depending on age[20]

Recent research suggests that lower doses of ketorolac (15mg instead of 30mg for IV administration) may be equally effective for pain relief while potentially reducing the risk of side effects[19]. This is an important consideration for safer use of this medication.

Side Effects and Safety Concerns

Like all medications, ketorolac can cause side effects. Common side effects include:

  • Gastrointestinal issues: Stomach pain, nausea, vomiting, or heartburn[21]
  • Drowsiness or dizziness: May affect ability to drive or operate machinery
  • Headache: Paradoxically, headaches can sometimes occur
  • Nasal discomfort: With intranasal formulations[7]
  • Eye irritation: With ophthalmic formulations

More serious potential risks include:

  • Kidney problems: Especially with prolonged use or in high-risk patients[22]
  • Gastrointestinal bleeding: Risk increases with longer use and higher doses[12]
  • Increased bleeding risk: May affect blood clotting, especially concerning for surgical patients
  • Cardiovascular risks: Slight increase in risk of heart attack or stroke with NSAIDs
  • Allergic reactions: Including severe reactions in some individuals

Due to these risks, ketorolac is typically limited to short-term use (5 days or less). It should be avoided in patients with certain conditions, including advanced kidney disease, active peptic ulcer disease, or history of gastrointestinal bleeding.

Special Populations

Pediatric Use

Ketorolac can be used in children, though dosing must be carefully adjusted based on weight. Studies have investigated the safety and effectiveness of ketorolac in pediatric patients for post-operative pain management[20]. The intranasal formulation has been studied in children aged 12-17 years, while other forms have been used in younger children under close medical supervision[23].

Use During Pregnancy and Breastfeeding

NSAIDs like ketorolac are generally not recommended during pregnancy, especially in the third trimester, as they may cause problems in the unborn baby or complications during delivery. Ketorolac does pass into breast milk and may harm a nursing baby. Always consult with your healthcare provider about the risks and benefits if you are pregnant or breastfeeding.

Elderly Patients

Older adults may be more sensitive to the side effects of ketorolac, especially kidney problems and gastrointestinal bleeding. Lower doses are typically recommended, usually half the standard adult dose[5].

Comparison with Other Medications

Ketorolac vs. Opioids

Compared to opioid pain medications, ketorolac:

  • Does not cause respiratory depression
  • Has no potential for addiction or dependence
  • Does not cause euphoria or sedation
  • Is less likely to cause constipation
  • May provide equivalent pain relief for certain types of pain[24]

Ketorolac vs. Other NSAIDs

Compared to other NSAIDs like ibuprofen or naproxen, ketorolac:

  • Is generally more potent for pain relief
  • Is available in more formulations (IV, IM, intranasal)
  • Has stricter limitations on duration of use (5 days maximum)
  • May have a higher risk of side effects at standard doses[5]

Comparisons in Specific Clinical Situations

In studies comparing ketorolac with other pain medications:

  • For renal colic, ketorolac combined with morphine was studied as a treatment option[3]
  • For post-operative pain after female pelvic reconstructive surgery, ketorolac was compared with standard acetaminophen plus ibuprofen regimens[1]
  • For ophthalmic use, ketorolac eye drops have been compared with nepafenac (Nevanac) and prednisolone acetate (Pred Forte) for effectiveness in reducing inflammation after eye surgeries[8]

Ongoing Research

Researchers continue to study ketorolac to find optimal dosing strategies and new applications. Some areas of current research include:

  • Topical gel formulations for treating acute gout flares and other localized pain conditions[9]
  • Anti-cancer effects in ovarian cancer cells, with potential applications in patients after cytoreductive surgery[25]
  • Lower-dose protocols that may provide equivalent pain relief with fewer side effects[2]
  • Pharmacokinetics in children to better understand appropriate dosing for pediatric patients[26]
  • Role in reducing opioid consumption after various surgical procedures[21]
  • Effects on tooth movement in orthodontic treatment and potential interactions with bone remodeling[27]

Ketorolac represents an important option in pain management, offering potent pain relief without the risks associated with opioid medications. When used appropriately for short-term treatment under medical supervision, it can be an effective component of pain management strategies for many conditions.

Formulation Common Doses Applications Key Findings from Trials
Intravenous (IV) 15-60 mg for adults; 0.5 mg/kg up to 30 mg for children Post-operative pain, Emergency pain relief, Labor and delivery, Musculoskeletal pain – Lower doses (15 mg) may be as effective as higher doses (30-60 mg) with fewer side effects
– Can reduce opioid consumption after cesarean sections
– Effective for acute pain management in sickle cell crisis
– May inhibit cancer cell adhesion and migration
Intranasal (SPRIX) 15.75 mg per spray (31.5 mg total dose) Acute pain management, Post-operative pain, Renal colic, Interstitial cystitis – Provides rapid pain relief without IV access
– Studied in pediatric patients with weight-based dosing
– Alternative to opioids in acute pain management
– Can be administered in outpatient settings
Ophthalmic (Acular LS, Acuvail) 0.4-0.5% solution Post-operative eye pain, Cataract surgery, Laser treatments, Corneal refractive surgery – Reduces inflammation and pain after eye procedures
– May prevent cystoid macular edema after cataract surgery
– Comparable efficacy to steroid eye drops with different side effect profile
– Can penetrate into anterior chamber and vitreous cavity
Topical Gel (Experimental) 12.5% w/w Acute gouty arthritis, Localized pain – Under investigation for treating acute gout flares
– May provide localized pain relief with lower systemic exposure
– Being studied for safety and pharmacokinetics in early trials
Intra-articular 30 mg Knee pain, Arthritic pain – Direct administration into joint may provide targeted relief
– Being compared to oral NSAIDs for efficacy
– May reduce need for systemic pain medications

FAQ

  • What is ketorolac and how does it work for pain management? Ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting the cyclooxygenase pathway, which reduces the production of prostaglandins and thromboxanes. These chemicals are responsible for inflammation, pain, and fever in the body. By blocking their production, ketorolac provides effective pain relief and reduces inflammation. It's available in several forms including intravenous (IV), oral, intranasal (Sprix), and topical ophthalmic solutions (Acular LS).
  • In what medical conditions is ketorolac being studied? Clinical trials are investigating ketorolac for numerous conditions including: post-operative pain management after surgeries (cesarean sections, orthopedic procedures, and vitreoretinal surgeries), acute renal colic, migraine headaches, interstitial cystitis pain flares, acute gouty arthritis, post-laser eye treatment discomfort, and as a potential alternative to opioids in pediatric pain management. It's also being studied in specialized applications like intranasal delivery for immediate pain relief and in comparison with other pain medications for optimal dosing strategies.
  • What are the different formulations of ketorolac available in clinical trials? Clinical trials are studying several formulations of ketorolac: 1) Intravenous (IV) ketorolac for immediate post-operative and emergency pain relief, 2) Intranasal ketorolac (SPRIX) for rapid pain management without requiring IV access, 3) Oral ketorolac tablets for ongoing pain control, 4) Topical ophthalmic solutions like Acular LS (0.4%) and Acuvail (0.45%) for eye-related pain and inflammation, and 5) Experimental formulations like topical ketorolac gel (12.5%) for conditions such as acute gouty arthritis. Each formulation has specific applications based on onset time, duration of action, and target tissue.
  • What are the advantages of ketorolac over opioid pain medications? The advantages of ketorolac over opioids include: 1) No risk of dependence or addiction, which is particularly important given the ongoing opioid crisis, 2) No respiratory depression, making it safer in many clinical situations, 3) No sedation, allowing patients to remain alert and functional, 4) Fewer gastrointestinal side effects like constipation compared to opioids, 5) Anti-inflammatory properties that address the underlying cause of pain, not just masking symptoms, and 6) Potentially reduced overall opioid consumption when used as part of multimodal pain management, as demonstrated in several clinical trials.
  • What are the potential side effects or safety concerns with ketorolac? While generally safer than opioids, ketorolac still has potential side effects and safety concerns: 1) Increased risk of bleeding due to its effect on platelets, 2) Potential for kidney injury, especially with higher doses or prolonged use, 3) Risk of gastrointestinal irritation, ulceration, or bleeding, 4) Cardiovascular risks similar to other NSAIDs, particularly with long-term use, 5) Possible allergic reactions in some individuals, and 6) Contraindications for certain populations such as those with kidney disease, bleeding disorders, or history of NSAID allergy. For these reasons, studies are examining lower doses that maintain efficacy while reducing risks, and ketorolac is typically limited to short-term use (under 5 days).

Ongoing Clinical Trials on KETOROLAC

  • Study on the Effects of Ketorolac and Pregabalin in Patients Undergoing Surgery for Early Estrogen Receptor-Positive Breast Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium

Glossary

  • Ketorolac Tromethamine: A non-steroidal anti-inflammatory drug (NSAID) that provides potent pain relief and anti-inflammatory effects by inhibiting prostaglandin synthesis. Available in intravenous, oral, intranasal, and topical formulations.
  • NSAID: Non-Steroidal Anti-Inflammatory Drug. A class of medications that reduce pain, decrease fever, prevent blood clots, and in higher doses, decrease inflammation. They work by inhibiting the enzyme cyclooxygenase (COX).
  • Cyclooxygenase pathway: An enzyme pathway that leads to the production of prostaglandins, which are involved in inflammation and pain. NSAIDs like ketorolac work by inhibiting this pathway.
  • COX-1 and COX-2: Two forms of the cyclooxygenase enzyme. COX-1 is constitutively expressed in most tissues and involved in homeostatic functions. COX-2 is primarily induced during inflammation. Ketorolac inhibits both forms.
  • Morphine Milligram Equivalents (MME): A standardized way to compare different opioids by converting their doses to an equivalent dose of morphine. Used to measure total opioid consumption in studies comparing pain management strategies.
  • Intranasal administration: Delivery of medication through the nose, allowing absorption through the nasal mucosa. This route provides rapid onset of action and avoids first-pass metabolism in the liver.
  • SPRIX: Brand name for intranasal ketorolac tromethamine, used for short-term management of moderate to moderately severe pain requiring analgesia at the opioid level.
  • Acular LS: Brand name for ketorolac tromethamine ophthalmic solution 0.4%, used to reduce ocular pain, burning and stinging following corneal refractive surgery or cataract extraction.
  • Selective Laser Trabeculoplasty (SLT): A laser procedure used to lower intraocular pressure in glaucoma by improving drainage of fluid from the eye.
  • Vaso-occlusive crisis: A painful episode that occurs when blood flow is obstructed by sickled red blood cells in people with sickle cell disease, causing severe pain and potential organ damage.
  • Photorefractive Keratectomy (PRK): A type of refractive surgery to correct myopia, hyperopia, and astigmatism by reshaping the cornea using a laser after removing the epithelium.
  • Pharmacokinetics (PK): The study of how drugs move through the body, including their absorption, distribution, metabolism, and excretion. Key PK parameters include Cmax (maximum concentration), Tmax (time to maximum concentration), and half-life.
  • Visual Analog Scale (VAS): A measurement instrument used to quantify subjective characteristics like pain that cannot be directly measured. Typically a straight line with endpoints representing extremes (e.g., 'no pain' to 'worst pain imaginable').
  • Verbal Numerical Rating Scale (VNRS): A pain assessment tool where patients rate their pain intensity verbally on a scale from 0 (no pain) to 10 (worst pain imaginable).
  • Cystoid Macular Edema (CME): A painless condition where multiple cyst-like (cystoid) areas of fluid appear in the macula (the central part of the retina), causing swelling. Can occur as a complication after eye surgery.
  • Minimally Important Difference (MID): The smallest change in a treatment outcome that a patient would identify as important. In pain studies, often defined as a 2-point reduction on a 0-10 pain scale.
  • Multimodal analgesia: The use of multiple different classes of pain medications or techniques simultaneously to improve pain control while minimizing side effects of any single agent.
  • RANK-L: Receptor Activator of Nuclear Factor Kappa-B Ligand, a protein involved in bone metabolism and remodeling. It plays a role in orthodontic tooth movement and can be affected by anti-inflammatory medications.
  • Non-inferiority trial: A type of clinical trial designed to demonstrate that a new treatment is not worse than a standard treatment by more than a pre-specified margin.

References

  1. https://clinicaltrials.gov/study/NCT04444830
  2. https://clinicaltrials.gov/study/NCT05641363
  3. https://clinicaltrials.gov/study/NCT01339624
  4. https://clinicaltrials.gov/study/NCT05248984
  5. https://clinicaltrials.gov/study/NCT04763876
  6. https://clinicaltrials.gov/study/NCT02885441
  7. https://clinicaltrials.gov/study/NCT01363063
  8. https://clinicaltrials.gov/study/NCT00478036
  9. https://clinicaltrials.gov/study/NCT06273813
  10. https://clinicaltrials.gov/study/NCT01363076
  11. https://clinicaltrials.gov/study/NCT02000401
  12. https://clinicaltrials.gov/study/NCT03727048
  13. https://clinicaltrials.gov/study/NCT02966288
  14. https://clinicaltrials.gov/study/NCT00366691
  15. https://clinicaltrials.gov/study/NCT00347204
  16. https://clinicaltrials.gov/study/NCT00576329
  17. https://clinicaltrials.gov/study/NCT01542190
  18. https://clinicaltrials.gov/study/NCT01609881
  19. https://clinicaltrials.gov/study/NCT01230463
  20. https://clinicaltrials.gov/study/NCT01819610
  21. https://clinicaltrials.gov/study/NCT03678675
  22. https://clinicaltrials.gov/study/NCT06579703
  23. https://clinicaltrials.gov/study/NCT02102516
  24. https://clinicaltrials.gov/study/NCT03111381
  25. https://clinicaltrials.gov/study/NCT01670799
  26. https://clinicaltrials.gov/study/NCT02297906
  27. https://clinicaltrials.gov/study/NCT05383820